Inclusion Criteria:

• Subject who agree to comply with protocol requirements and instructions and who provide signed and dated written informed consent.*
• Male and female subjects, ≥20 years of age (at the time of informed consent) with chronic liver disease. *
• Child-Pugh score <=9 (See Appendix 2).
• A baseline platelet count <50,000/mcL.
• A baseline serum sodium level >130mEq/L.
• Haemoglobin concentration >8g/dL stable for at least 4 weeks.
• A female is eligible to enter and participate in the study if she is of:*

Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any female who:

• Has had a hysterectomy
• Has had a bilateral oophorectomy (ovariectomy)
• Has had a bilateral tubal ligation
• Is post-menopausal (demonstrate total cessation of menses for greater than one year) Childbearing potential, has a negative urine and/or serum pregnancy test at screening, and within the 24 hour period prior to the first dose of investigational product and uses one of the following acceptable methods of contraception:
• Complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical study, and for 28 days after completion or premature discontinuation from the study to account for the elimination of the study drug (minimum of 5 half-lives).
• Any intrauterine device (IUD) with a documented failure rate of less than 1% per year.
• Double-barrier contraception (condom with spermicidal jelly, or diaphragm with spermicide).
• Male partner who is sterile (diagnosed by a qualified medical professional) prior to the female subject's study entry and is the sole sexual partner for that female.
• Oral contraceptive (combined).
• Any other contraceptive method with a documented failure rate of <1% per year.
• Subject has no physical limitation to ingest and retain oral medication.*

Exclusion Criteria:

• Subjects with known or suspected hypersensitivity, intolerance or allergy to any of the ingredients in eltrombopag tablets.*
• Evidence of portal vein thrombosis on abdominal imaging (ultrasound with Doppler or appropriate MRI/CT imaging techniques) within 3 months of study start.*
• History of arterial or venous thrombosis (including Budd-Chiari Syndrome),*

AND ≥ two of the following risk factors*:

• hereditary thrombophilic disorders (e.g. Factor V Leiden, ATIII deficiency, etc.)
• hormone replacement therapy
• systemic contraception therapy (containing oestrogen)
• smoking
• diabetes
• hypercholesterolemia
• medication for hypertension or cancer
• HIV infection.*
• History of drug/alcohol abuse or dependence within 1 year prior to screening.*
• Any disease condition associated with current active WHO Grade 3 or 4 bleeding (See Appendix 3).
• Active infection requiring systemic antibiotic therapy. **
• Pregnant, nursing mothers, women who may be pregnant, or women who plan to become pregnant during the time of study participation.
• Treatment with platelet transfusion within 2 weeks prior to Day 1.
• Treatment with interferon within 4 weeks prior to Day 1.
• Treatment with an investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
• History of platelet agglutination abnormality that prevents reliable measurement of platelet counts.*
• History of porphyria.*
• Subjects who are deemed unsuitable for the study by the investigator (or subinvestigator).